使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, and welcome to Aveanna Healthcare Holdings Inc. first-quarter 2026 earnings call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A. At this time, I'd like to turn the call over to Debbie Stewart, Aveanna's Chief Accounting Officer. Thank you. You may begin.
早安,歡迎參加 Aveanna Healthcare Holdings Inc. 2026 年第一季財報電話會議。今天的電話會議將被錄音,我們安排了一小時進行管理層準備發言與問答。此刻,我想把電話交給 Aveanna 首席會計官 Debbie Stewart。謝謝。您可以開始了。
Deborah Stewart - Senior Vice President, Chief Accounting Officer
Deborah Stewart - Senior Vice President, Chief Accounting Officer
Good morning, welcome to Aveanna's first-quarter 2026 earnings call. I am Debbie Stewart, the company's Chief Accounting Officer. With me today is Jeff Shaner, our Chief Executive Officer; and Matt Buckhalter, our Chief Financial Officer.
早安,歡迎參加 Aveanna 2026 年第一季財報電話會議。我是公司首席會計官 Debbie Stewart。今天與我一同出席的有:我們的執行長 Jeff Shaner,以及財務長 Matt Buckhalter。
During this call, we will make forward-looking statements. Risk factors that may impact those statements and could cause actual future results to differ materially from currently projected results are described in this morning's press release and the reports we file at the SEC. The company does not undertake any duty to update such forward-looking statements.
在本次電話會議中,我們將發表前瞻性陳述。可能影響這些陳述、並可能導致未來實際結果與目前預期結果出現重大差異的風險因素,已載於今早的新聞稿以及我們向美國證券交易委員會(SEC)提交的報告中。本公司不承擔更新此類前瞻性陳述的任何義務。
Additionally, during today's call, we will discuss certain non-GAAP measures which we believe can be useful in evaluating our performance. The presentation of this additional information should not be considered in isolation or as a substitute for results prepared in accordance with GAAP. A reconciliation of these measures can be found in this morning's press release, which is posted on our website, aveanna.com, and in our most recent quarterly report on Form 10-Q when filed.
此外,在今天的電話會議中,我們將討論若干非 GAAP 指標,我們認為這些指標有助於評估我們的表現。此等補充資訊不應被孤立看待,亦不應作為依 GAAP 編製之結果的替代。相關指標的調節表可見於今早的新聞稿(已發布於我們的網站 aveanna.com),以及在提交後我們最新的 Form 10-Q 季度報告中。
With that, I will turn the call over to Aveanna's Chief Executive Officer, Jeff Shaner. Jeff?
接下來,我將把電話交給 Aveanna 執行長 Jeff Shaner。Jeff?
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Thank you, Debbie. Good morning, and thank you for joining us today. We appreciate each of you investing your time this morning to better understand our Q1 results and how we are moving Aveanna forward in 2026.
謝謝你,Debbie。早安,感謝各位今天加入。我們感謝各位在今早投入時間,以更了解我們第一季的業績,以及我們在 2026 年如何推動 Aveanna 持續向前。
My initial comments will briefly highlight our first quarter results, along with the steps we are taking to address the labor markets and our ongoing efforts with government and preferred payers to create additional capacity. I will provide updates on the recently announced Family First Homecare acquisition and how we are thinking about our 2026 strategic initiatives and our enhanced guidance before turning the call over to Matt.
我先簡要說明第一季的業績重點,以及我們為因應勞動市場所採取的措施,並更新我們與政府及優先付款方(preferred payers)合作、以創造更多服務量能的持續努力。我也會就近期宣布的 Family First Homecare 收購案提供最新進展,並說明我們對 2026 年策略性計畫與上調後指引的思考,之後再把電話交給 Matt。
Moving to highlights for the first quarter. Revenue for the first quarter was approximately $648 million, representing a 15.9% increase over the prior year period. First quarter adjusted EBITDA was $84.4 million, representing a 25.2% increase over the prior year period, primarily due to the improved rate and volume environment and continued operational efficiencies.
先看第一季重點。第一季營收約為 6.48 億美元,較去年同期成長 15.9%。第一季調整後 EBITDA 為 8,440 萬美元,較去年同期成長 25.2%,主要受惠於費率與量能環境改善,以及持續的營運效率提升。
As we have previously discussed, the labor environment represented the primary challenge that we needed to address to see Aveanna resume the growth trajectory that we believed our company could achieve. It is important to note that our industry does not have a demand problem. The demand for home and community-based care continues to be strong, with both state and federal governments and managed care organizations asking for solutions that create more capacity while reducing the total cost of care.
如我們先前所討論,勞動環境是我們必須解決的主要挑戰,才能讓 Aveanna 回到我們相信公司可達成的成長軌道。需要強調的是,我們的產業並不存在需求問題。居家與社區式照護的需求仍然強勁,州與聯邦政府以及管理式照護組織(MCO)都在尋求能在降低整體照護成本的同時、創造更多服務量能的解決方案。
Our Q1 results highlight that we continue to align our objectives with those of our preferred payers and government partners. By focusing our clinical capacity on our preferred payers, we achieved solid year-over-year growth in all three of our business segments. We also experienced improvement in our caregiver hiring and retention trends by aligning our efforts with those payers willing to engage with us on enhanced reimbursement rates and value-based agreements. While we continue to operate in a challenging environment, our preferred payer strategy supports our ability to achieve accelerated growth rates in all three of our business segments.
我們第一季的結果顯示,我們持續讓自身目標與優先付款方及政府合作夥伴的目標一致。透過將臨床量能聚焦於優先付款方,我們在三大業務部門皆實現穩健的年增成長。我們也透過與願意就提高報銷費率與價值導向協議(value-based agreements)與我們合作的付款方對齊努力方向,看到照護人員招募與留任趨勢改善。雖然我們仍在具挑戰的環境中營運,但優先付款方策略支持我們在三大業務部門達成更快的成長速度。
Since our fourth quarter earnings call, I am pleased with the continued progress we have made on several of our rate improvement initiatives with both government and payer partners, as well as continued signs of improvement in the caregiver labor market. Specifically, as it relates to our Private Duty Services business, our government affairs strategy for 2026 was twofold.
自第四季財報電話會議以來,我很高興看到我們在多項費率改善計畫上,無論是政府或付款方合作夥伴,都持續取得進展,同時照護人員勞動市場也持續出現改善跡象。具體而言,就我們的私人護理服務(Private Duty Services,PDS)業務而言,我們 2026 年的政府事務策略有兩個面向。
First, we continue to advocate for Medicaid rate integrity on behalf of children with complex medical conditions. Our strong advocacy presence with both federal and state legislatures across our national footprint enhances our value proposition.
第一,我們持續代表具有複雜醫療狀況的兒童,倡議 Medicaid 費率的完整性。我們在全國營運版圖中,於聯邦與州立法機構皆具備強而有力的倡議能量,進一步提升我們的價值主張。
Second, we expect to achieve mid-single-digit state rate enhancements in 2026. As of Q1, we have received three Private Duty Services state rate wins and believe we will achieve our goals as states complete their annual budget processes. After three years of meaningful rate increases in a majority of our PDS states, we are in a very stable rate environment and are shifting our focus to cost of living and wage rate adjustments.
第二,我們預期在 2026 年可達成各州費率中個位數(mid-single-digit)的提升。截至第一季,我們已取得三項 PDS 州費率調升成果,並相信隨著各州完成年度預算流程,我們將達成目標。在多數 PDS 州經歷三年顯著的費率上調後,我們目前處於非常穩定的費率環境,並將重點轉向生活成本與薪資水準調整。
Moving to our PDS preferred payer initiatives. Aveanna's preferred payer strategy continues to gain momentum and allows us to invest in caregiver wages and recruitment efforts to accelerate hiring and staffing of nurses.
接著談 PDS 的優先付款方計畫。Aveanna 的優先付款方策略持續累積動能,使我們能投資於照護人員薪資與招募工作,以加速護理師的招募與排班配置。
Our preferred payer goal for 2026 is to achieve eight additional agreements for a total of 38 preferred payers. We signed four preferred payer agreements in Q1 and are well on our way to achieving our 2026 target. Additionally, our Q1 PDS preferred payer agreements accounted for approximately 60% of our total Private Duty Services MCO volumes, up from 57% at the end of 2025. This positive momentum in preferred payer volumes continues to highlight the shift in our caregiver capacity and recruitment efforts towards our preferred payer partners.
我們 2026 年的優先付款方目標是再新增 8 份協議,使優先付款方總數達到 38 家。我們在第一季簽署了 4 份優先付款方協議,正穩步邁向 2026 年目標。此外,我們第一季的 PDS 優先付款方協議約占私人護理服務 MCO 總量的 60%,高於 2025 年底的 57%。優先付款方量能的正向動能,持續凸顯我們正將照護人員量能與招募資源轉向優先付款方合作夥伴。
Moving to our preferred payer progress in Home Health. Our goal for 2026 is to maintain our episodic payer mix above 75% while returning to a more normalized growth rate. I am pleased to report in Q1, our episodic mix was approximately 80%, and our total episodic volume growth was 23.1% compared with the prior year period.
再看居家健康(Home Health)業務的優先付款方進展。我們 2026 年的目標是在回到較正常的成長速度的同時,將按療程計價(episodic)的付款方組合維持在 75% 以上。我很高興報告,第一季我們的按療程計價占比約為 80%,而按療程計價的總量較去年同期成長 23.1%。
The continued investment in clinical outcomes, sales resources, and a focused approach to growth is deriving results with Q1 total admissions of approximately 11,000 or 13.4% organic growth over the prior year period. We exited 2025 with 45 preferred payer agreements in Home Health and expected to add five agreements in 2026 for a total of 50.
持續投資於臨床結果、銷售資源,以及聚焦式的成長策略,已在第一季帶來成果:總收案(admissions)約 11,000 件,較去年同期有 13.4% 的有機成長。2025 年底我們在居家健康業務擁有 45 份優先付款方協議,並預期 2026 年再新增 5 份,使總數達到 50 份。
As of Q1, I am pleased to report that we added four additional preferred payer agreements and are well on our way to exceeding our goal of 50 preferred payers in Home Health in 2026. Our dedicated focus on aligning our Home Health caregiver capacity with those payers willing to reimburse us on an episodic basis has led to double-digit year-over-year growth in Home Health total admissions and episodes, as well as improvement in our clinical and financial outcomes.
截至第一季,我很高興報告我們已新增 4 份優先付款方協議,正穩步邁向在 2026 年居家健康業務優先付款方數量超越 50 家的目標。我們專注於將居家健康照護人員量能與願意以按療程方式報銷的付款方對齊,帶動居家健康總收案與療程數(episodes)皆呈現雙位數年增,同時也改善了臨床與財務成果。
Finally, as we have achieved our desired preferred payer model in Private Duty Services and Home Health & Hospice, we are continuing with a similar strategy in our Medical Solutions business. As we exited 2025, we had 18 preferred payer agreements in Med Solutions and expected that number to grow to 25 by the end of 2026.
最後,隨著我們在私人護理服務以及居家健康與安寧(Home Health & Hospice)已達成理想的優先付款方模式,我們也在醫療解決方案(Medical Solutions)業務延續類似策略。2025 年底,我們在醫療解決方案擁有 18 份優先付款方協議,並預期到 2026 年底增至 25 份。
As of Q1, we signed two additional agreements for a total of 20 preferred payer agreements to date. Our gross margins have stabilized in our desired range as we align our clinical capacity with those payers that value our services and pay us in a timely fashion.
截至第一季,我們再簽署 2 份協議,使目前優先付款方協議總數達到 20 份。隨著我們將臨床量能與重視我們服務、並能及時付款的付款方對齊,我們的毛利率已在目標區間內趨於穩定。
I am pleased with our Q1 volume growth in Med Solutions of approximately 93,000 UPS or positive 4.5% over the prior year period. We think about Medical Solutions growth in 2026, I would expect us to remain in the mid-single digits for the next few quarters and then return to double-digit growth by the end of the year. We are encouraged by our rate increases, preferred payer agreements, and subsequent growth in our businesses.
我對第一季醫療解決方案的量能成長感到滿意,約為 93,000 UPS,較去年同期增加 4.5%。就 2026 年醫療解決方案的成長而言,我預期未來幾季將維持在中個位數成長,並在年底前回到雙位數成長。我們對費率上調、優先付款方協議,以及隨之而來的業務成長感到鼓舞。
Our company has demonstrated a stable return to organic growth as we achieve our rate goals previously discussed. Home and community-based care will continue to grow. Aveanna is a comprehensive platform with a diverse payer base providing cost-effective, high-quality alternative to higher-cost care settings.
隨著我們達成先前討論的費率目標,公司已展現有機成長穩定回歸的態勢。居家與社區式照護將持續成長。Aveanna 是一個具完整性的綜合平台,擁有多元的付款方基礎,能以具成本效益且高品質的方式,提供相較高成本照護場域的替代方案。
Turning to our recently announced transaction to acquire Family First Homecare, a Florida-based company with a great reputation for quality in-home pediatric care. I would like to send my warm welcome to the Family First teammates. I am thrilled to continue our acquisition growth story with great companies like Thrive Skilled Pediatric Care and Family First Homecare. Both companies continue to build upon the Aveanna brand of high quality, compassionate care in the most cost-effective setting, the comfort of our patient's home.
接著談我們近期宣布的交易:收購 Family First Homecare——一家位於佛羅里達州、在高品質居家兒科照護方面享有盛譽的公司。我想向 Family First 的夥伴們致上誠摯歡迎。我很高興能與 Thrive Skilled Pediatric Care 與 Family First Homecare 這樣優秀的公司一起,延續我們透過併購推動成長的故事。兩家公司都持續在最具成本效益的照護場域——病患家中——建立並強化 Aveanna 高品質、富同理心的照護品牌。
We continue to work through the regulatory approval process and expect the transaction will close sometime in late Q2. I look forward to updating you on our progress in the coming months. Let me comment on our strategic plan and enhanced outlook for 2026. We will focus our efforts on 5 primary strategic initiatives.
我們持續推進監管核准流程,並預期交易將於第二季末左右完成交割。我期待在未來幾個月向各位更新進展。接著我談談我們 2026 年的策略計畫與上調後展望。我們將把資源聚焦於 5 項主要策略性計畫。
First, strengthening our partnerships with government partners and preferred payers to create additional capacity and growth. Second, improving clinical outcomes and customer engagement scores while lowering the total cost of care. Third, implementing high-priority artificial intelligence and automation efforts to improve operational efficiency and productivity gains. Fourth, growing through acquisitions while improving net leverage and free cash flow.
第一,強化與政府合作夥伴及優先付款方的合作關係,以創造更多量能與成長。第二,在降低整體照護成本的同時,改善臨床結果與客戶互動評分。第三,推動高優先級的人工智慧與自動化工作,以提升營運效率並帶來生產力提升。第四,透過併購推動成長,同時改善淨槓桿與自由現金流。
Finally, engaging our leaders and employees in delivering our Aveanna mission. Based on the strength of our first quarter results and the continued execution of our key strategic initiatives, we are increasing our full year revenue and adjusted EBITDA guidance to a revenue range of $2.56 billion to $2.58 billion and an adjusted EBITDA range of $328 million to $332 million.
最後,讓我們的領導團隊與員工共同投入,落實 Aveanna 的使命。基於我們第一季業績的強勁表現以及關鍵策略計畫的持續執行,我們上調全年營收與調整後 EBITDA 指引:全年營收區間提高至 25.6 億美元至 25.8 億美元,調整後 EBITDA 區間提高至 3.28 億美元至 3.32 億美元。
We believe this enhanced 2026 outlook provides a prudent view considering the challenges we still face with the evolving environment and does not include the impact of Family First acquisition. As I reflect on the strong start to 2026, I want to take a moment and comment on our second annual Aveanna Cares Month of Community Service. We dedicate the month of April to not only focusing on our mission, but living that mission in our 379 communities.
我們認為,這份強化後的 2026 年展望在考量我們仍面臨的環境演變挑戰下,提供了審慎的觀點,且未納入 Family First 併購案的影響。回顧 2026 年的強勁開局,我想花點時間談談我們第二屆年度「Aveanna Cares 社區服務月」。我們將四月整個月份用於不僅聚焦於使命,更是在我們的 379 個社區中實踐這份使命。
Aveanna Cares is an extension of the care we provide families every day, we are proud to give back, help others, and strengthen our communities and our teams through our volunteering efforts. We set an ambitious goal this year to serve 7,500 volunteer hours, I am extremely proud to announce that our Aveanna family completed over 9,000 total volunteer hours.
Aveanna Cares 是我們每天為家庭提供照護的延伸;我們以回饋社會、幫助他人為榮,並透過志工服務強化我們的社區與團隊。今年我們設定了具企圖心的目標:完成 7,500 小時的志工服務;我非常自豪地宣布,Aveanna 大家庭總計完成了超過 9,000 小時的志工服務。
Our teams held approximately 200 event, volunteer events nationwide and lived our core values while giving back to important local charities that support children, adults, and seniors in our communities. I look forward to raising the bar in 2027 with plans to further expand our Aveanna Cares impact across the country.
我們的團隊在全國舉辦了約 200 場活動與志工服務,並在回饋重要在地慈善機構(支持我們社區中的兒童、成人與長者)時,實踐了我們的核心價值。我期待在 2027 年再創新高,並計畫進一步擴大 Aveanna Cares 在全國的影響力。
With that, let me turn the call over to Matt to provide further details on the quarter and our 2026 outlooks. Matt?
接下來,我把電話交給 Matt,請他提供本季與我們 2026 年展望的更多細節。Matt?
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
Thank you, Jeff, and good morning. I'll first talk about our first quarter financial results and liquidity before providing additional details on our refreshed outlook for 2026. Starting with the top line, we saw revenues rise 15.9% over the prior year period to $647.9 million.
謝謝你,Jeff,大家早安。我將先談第一季的財務結果與流動性,接著提供我們更新後 2026 年展望的更多細節。先從營收來看,我們的營收較去年同期成長 15.9%,達到 6.479 億美元。
We achieved year-over-year revenue growth in all three of our operating divisions by our Home Health & Hospice, by the Private Duty Services, and Medical Solutions divisions, which grew by 17.4%, 16.4%, and 7.4% compared to the prior year period. Consolidated gross margin was $205.4 million, or 31.7%. Consolidated adjusted EBITDA was $84.4 million, a 25.2% increase as compared to the prior year period. This growth reflects an improved rate environment, increased volumes, as well as enhanced operational efficiencies.
我們三個營運事業部門皆達成年增營收成長:居家健康與安寧照護(Home Health & Hospice)、私人照護服務(Private Duty Services)以及醫療解決方案(Medical Solutions)部門,較去年同期分別成長 17.4%、16.4% 與 7.4%。合併毛利為 2.054 億美元,毛利率為 31.7%。合併調整後 EBITDA 為 8,440 萬美元,較去年同期增加 25.2%。此成長反映了更有利的費率環境、服務量提升,以及營運效率的改善。
Taking a deeper look into each of our segments. Starting with Private Duty Services, revenue for the quarter was approximately $536 million, a 16.4% increase, was driven by approximately 12.1 million hours of care, a volume increase of 10.7% over the prior year. Q1 revenue per hour of $44.43 was up 5.7% compared to the prior year quarter, primarily driven by growth in preferred payer volume and updated reimbursement agreements. We remain optimistic about our ability to attract caregivers and address market demands for our services when we obtain acceptable reimbursement rates.
更深入檢視各事業部門。先看私人照護服務(Private Duty Services),本季營收約 5.36 億美元,年增 16.4%,主要由約 1,210 萬小時的照護時數所帶動,服務量較去年同期增加 10.7%。第一季每小時營收為 44.43 美元,較去年同期上升 5.7%,主要受惠於偏好付款方(preferred payer)服務量成長以及更新後的給付協議。我們仍對在取得可接受的給付費率時,吸引照護人員並滿足市場對我們服務需求的能力保持樂觀。
Turning to our cost of labor and gross margin metrics, we achieved $149.2 million of gross margin, or 27.9%. The cost of revenue rate of $32.05 in Q1 was up $2.17, or 8.1% from the prior year period. Our Q1 spread per hour was $12.38, reflecting continued normalization driven in part by ongoing caregiver wage adjustments, supporting higher volumes and improving clinical outcomes.
接著看人力成本與毛利指標,我們達成毛利 1.492 億美元,毛利率為 27.9%。第一季營收成本率為 32.05 美元,較去年同期增加 2.17 美元(增幅 8.1%)。第一季每小時價差(spread per hour)為 12.38 美元,反映在持續進行的照護人員薪資調整等因素帶動下,價差持續回歸常態,同時支撐更高的服務量並改善臨床結果。
Moving on to our Home Health & Hospice segment. Revenue for the quarter was approximately $66.6 million, a 17.4% increase over the prior year. Revenue was driven by 11,000 total admissions, with approximately 80% being episodic and 14,900 total episodes of care, up 23.1% from the prior year quarter.
再來看居家健康與安寧照護(Home Health & Hospice)部門。本季營收約 6,660 萬美元,較去年同期成長 17.4%。營收由 11,000 件總入院(admissions)所帶動,其中約 80% 為按療程計(episodic),總照護療程(episodes of care)為 14,900 件,較去年同期增加 23.1%。
Medicare revenue per episode was $3,167, up 0.5% from the prior year quarter. Our episodic focus has accelerated our margin expansion and improved our clinical outcomes. With episodic admissions well over 75%, we have achieved our goal of rightsizing our margin profile and enhancing our clinical offerings. We are pleased with our Q1 gross margin of 53.7%, representing our continued focus on cost initiatives to achieve our targeted margin profile.
每療程 Medicare 營收為 3,167 美元,較去年同期增加 0.5%。我們對按療程計(episodic)的聚焦加速了毛利率擴張並改善臨床結果。隨著按療程計入院占比遠高於 75%,我們已達成調整毛利結構(rightsizing our margin profile)並強化臨床服務的目標。我們對第一季 53.7% 的毛利率感到滿意,這也展現我們持續聚焦成本措施,以達成目標毛利結構。
Our Home Health & Hospice platform is dedicated to creating value through effective operational management and the delivery of exceptional patient care. Now, to our Medical Solutions segment results for Q1. During the quarter, we produced revenue of $45.7 million, up 7.4% over the prior year period.
我們的居家健康與安寧照護平台致力於透過有效的營運管理與提供卓越的病患照護來創造價值。接著看第一季醫療解決方案(Medical Solutions)部門的表現:本季營收為 4,570 萬美元,較去年同期成長 7.4%。
Revenue was driven by approximately 93,000 unique patients served, and revenue per UPS of approximately $491, up 2.9% over the prior year period. Gross margin was approximately $20.4 million, or 44.7% for the quarter. As Jeff mentioned, we are in the final stages of implementing our preferred payer strategy in Medical Solutions by aligning our capacity with those payers that value our resources and appropriately reimburse us for the services we provide.
營收主要由約 93,000 名服務的獨立病患(unique patients served)所帶動,每 UPS 營收約 491 美元,較去年同期增加 2.9%。本季毛利約 2,040 萬美元,毛利率為 44.7%。如 Jeff 所提,我們正處於在醫療解決方案部門落實偏好付款方策略的最後階段,透過將產能與重視我們資源、並能就我們提供的服務給予適當給付的付款方進行對齊。
As a result, we expect margins to normalize and UPS to continue to accelerate its growth in the back half of 2026. In summary, we remain focused on keeping our patients' care at the center of everything we do. It is clear that aligning caregiver capacity with preferred payers who value our partnership is the right path forward at Aveanna.
因此,我們預期毛利率將回歸常態,且 UPS 在 2026 年下半年將持續加速成長。總結而言,我們仍專注於把病患照護置於我們一切工作的核心。很明顯,將照護人力產能與重視我們合作關係的偏好付款方對齊,是 Aveanna 正確的前進方向。
With the strong momentum through Q1, we are optimistic these trends will continue into 2026. We would continue to pass through wage improvements and other benefits to our caregivers and the ongoing effort to better improve volumes. Moving to our balance sheet and liquidity.
在第一季的強勁動能帶動下,我們對這些趨勢在 2026 年延續保持樂觀。我們將持續把薪資改善與其他福利回饋給照護人員,並持續努力進一步提升服務量。接著談資產負債表與流動性。
At the end of the first quarter, we had liquidity of approximately $525 million, representing cash on hand of approximately $189 million, $110 million of availability under our securitization facility, and approximately $226 million of availability on our revolver, which was undrawn as of the end of the quarter. We had $24.5 million in outstanding letters of credit at the end of Q1. On the debt service front, we had approximately $1.48 billion of variable rate debt at the end of Q1.
截至第一季末,我們的流動性約為 5.25 億美元,包括約 1.89 億美元的手頭現金、證券化融資工具(securitization facility)下約 1.10 億美元的可用額度,以及循環信貸(revolver)約 2.26 億美元的可用額度;該循環信貸在季末時尚未動用。第一季末我們尚有 2,450 萬美元的未償信用狀(letters of credit)。在債務償付方面,第一季末我們約有 14.8 億美元的浮動利率債務。
Of this amount, $520 million is hedged with fixed rate swaps and $880 million is subject to an interest rate cap, which limits further exposure to increases in SOFR above 3%. Accordingly, substantially all our variable rate debt is hedged. Our interest rate swaps extend through June 2026, and our interest rate caps extend through February 2027. In anticipation of the swap expiration, we entered into an additional interest rate cap agreement effective July 2026. This agreement limits exposure on $520 million of variable rate debt to increases in SOFR above 4% through December 2029. Looking at year-to-date cash flow, cash generated by operating activities was $4.3 million, and free cash flow was minus $3.8 million.
其中 5.20 億美元透過固定利率交換(fixed rate swaps)進行避險,8.80 億美元則受利率上限(interest rate cap)保護,將 SOFR 高於 3% 的進一步上升曝險加以限制。因此,我們幾乎所有浮動利率債務均已避險。我們的利率交換合約期限至 2026 年 6 月,利率上限合約期限至 2027 年 2 月。為因應交換合約到期,我們已簽訂一份自 2026 年 7 月生效的額外利率上限協議;該協議將 5.20 億美元浮動利率債務在 SOFR 高於 4% 的上升曝險加以限制,期限至 2029 年 12 月。就年初至今的現金流而言,營運活動產生的現金為 430 萬美元,自由現金流為負 380 萬美元。
We are encouraged by our strong cash collections and cost efficiency efforts, which drove solid operating and free cash flow in 2025. We expect similar cash flow performance in 2026. As a reminder, the first quarter is typically our seasonal low point for both operating and free cash flow, with improvement expected throughout the rest of the year.
我們對強勁的現金回收與成本效率提升措施感到鼓舞,這些因素在 2025 年帶動了穩健的營運現金流與自由現金流。我們預期 2026 年也將有類似的現金流表現。提醒一下,第一季通常是我們營運現金流與自由現金流的季節性低點,預期在今年其餘期間將逐步改善。
Before I hand the call over to the operator for Q&A, let me take a moment to address our raised outlook for 2026. As Jeff mentioned, we expect full year 2026 revenue range of $2.56 billion to $2.58 billion and adjusted EBITDA range of $328 million to $332 million. Consistent with our standard practice, our full year 2026 guidance excludes the pending Family First acquisition, which we expect to close in late Q2.
在我把電話交給接線員進行問答之前,我想花點時間說明我們上調後的 2026 年展望。如 Jeff 所提,我們預期 2026 年全年營收區間為 25.6 億美元至 25.8 億美元,調整後 EBITDA 區間為 3.28 億美元至 3.32 億美元。依照我們一貫作法,2026 年全年指引不包含尚待完成的 Family First 併購案,我們預期該交易將於第二季末完成。
As we reflect on our Q1 results, I'd like to take a moment to express my sincere gratitude to our Aveanna teammates. These strong results would not have been possible without your hard work and dedication. Looking ahead, I'm excited for the continued execution of our 2026 strategic plan and look forward to providing you with further updates at the end of Q2.
回顧第一季成果,我想藉此向 Aveanna 的同仁們致上最誠摯的感謝。若沒有各位的辛勤付出與投入,這些亮眼成果不可能達成。展望未來,我對 2026 年策略計畫的持續落實感到振奮,並期待在第二季結束時向各位提供更多更新。
With that, let me turn the call over to the operator.
接下來,我把電話交給接線員。
Operator
Operator
(Operator Instructions)
(接線員指示)
Ben Hendrix, RBC Capital Markets.
Ben Hendrix,RBC Capital Markets。
Ben Hendrix - Assistant Vice President
Ben Hendrix - Assistant Vice President
Just wanted to get some comments on the regulatory backdrop, specifically with the Home Health moratorium on new Medicare licensure announced yesterday. Just wanted to get some of your overall thoughts, any impact it's having on your acquisition strategy to the extent to which it might impact acquisitions like Family First or others. Any kind of comments you can give on the backdrop? Thanks.
我想請教一下監管環境的看法,特別是昨天宣布的居家健康(Home Health)新增 Medicare 執照暫停(moratorium)。想聽聽你們整體的想法,以及它對你們併購策略可能造成的影響,包括是否會影響像 Family First 或其他併購案。能否就整體背景提供一些評論?謝謝。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Morning, Ben, and well, Matt won the bet because we figured that would be the first question, the second question, third question. I appreciate you just getting us right there. All kidding aside, Ben, I think if I think macro industry-wide, let's start with the industry, and then we'll come back to Aveanna. Dr. Oz and CMS, the administration, have been pretty deliberate with their messaging around fraud, waste, and abuse now for at least one year, if not longer. I view yesterday's CMS announcement regarding the Home Health & Hospice six-month enrollment moratorium as consistent with Dr. Oz's messaging over the last six months to one year.
早安,Ben,嗯,Matt 贏了這個賭注,因為我們判斷那會是第一個問題、第二個問題、第三個問題。我很感謝你直接把我們帶到重點。玩笑歸玩笑,Ben,我想如果從宏觀、全產業的角度來看,我們先從產業談起,然後再回到 Aveanna。Oz 醫師與 CMS、政府部門,至少在過去一年(甚至更久)一直相當明確地傳達他們對於詐欺、浪費與濫用的立場。我認為,CMS 昨天就「居家健康與安寧療護(Home Health & Hospice)」發布的為期六個月的新增登記暫停令(enrollment moratorium),與 Oz 醫師過去六個月至一年的訊息是一致的。
I'd be remiss if, as an industry participant to say that we're disappointed that a nationwide moratorium is not the way to solve L.A. county's specific targeted fraud, waste, and abuse. I do think it's consistent with the messaging that CMS has been sharing the last six months. If I drill down to Aveanna and Family First, it has absolutely no impact, zero impact on Aveanna. The way we have read it has zero impact on our 2026 business plan, our 2027 business plan. Our Home Health & Hospice business was built through M&A and then organic growth.
作為產業參與者,如果我不說我們對於以全國性暫停令來處理洛杉磯郡特定、鎖定式的詐欺、浪費與濫用問題感到失望,那就不夠坦白。我確實認為這與 CMS 過去六個月所傳達的訊息一致。如果聚焦到 Aveanna 與 Family First,這對 Aveanna 完全沒有影響,零影響。我們的解讀是,對我們 2026 年的營運計畫、2027 年的營運計畫都沒有影響。我們的居家健康與安寧療護業務是透過併購建立,之後再以有機成長擴張。
For that part of it, we feel positive and pleased that the rule was thoughtful, the moratorium was thoughtful, to not penalize current Medicare beneficiaries and current providers. We would like in this next six months, with the National Alliance for Care at Home and all of our industry peers to work with Dr. Oz and CMS to really target the areas where fraud, waste, and abuse are occurring, specifically places like L.A. county, because this does punish rural type healthcare, right? Rural healthcare needs more providers. They need more robust Home Health & Hospice providers. We want to work with the administration, and we think the thoughtfulness of how Dr. Oz has approached things, that opportunity will avail itself.
就這部分而言,我們感到正面且欣慰,因為這項規則、這項暫停令的設計是審慎的,沒有去懲罰現有的 Medicare 受益人與現有的供應商。我們希望在接下來六個月,能與 National Alliance for Care at Home 以及所有同業夥伴一起,和 Oz 醫師及 CMS 合作,真正鎖定詐欺、浪費與濫用正在發生的區域,特別是像洛杉磯郡這樣的地方,因為這確實會懲罰到鄉村型醫療,對吧?鄉村醫療需要更多供應商,需要更健全的居家健康與安寧療護供應商。我們希望與政府合作,也認為 Oz 醫師處理事情的審慎態度,會讓這樣的合作機會得以實現。
We expect to hear this question a lot today, and I'll reiterate, absolutely zero impact on our 2026 guidance, our results, and our ability to grow the business successfully.
我們預期今天會常常被問到這個問題,我再重申一次:對我們 2026 年的指引、我們的結果,以及我們成功成長業務的能力,完全是零影響。
Ben Hendrix - Assistant Vice President
Ben Hendrix - Assistant Vice President
Great. Thanks. Just to be clear, there's nothing that involved in the transfer of a Medicare licensure that would require you guys to kind of reapply that might be impacted by this by this moratorium.
很好,謝謝。只是要確認一下,Medicare 執照的移轉並沒有任何需要你們重新申請、而可能會受到這項暫停令影響的事項,對嗎?
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
No. I think, the CMS did a nice job yesterday in releasing the Q&A, right. You were able to kind of read the Q&A and the 36-month rule has been in place for at least a decade, maybe even two. You still have to adhere to the 36-month rule in any targeted acquisition on Home Health or Hospice assets, and that's been in place. Nothing new there. No, nothing that limits our ability to do normal things like move an address or the normal things that we do.
沒有。我認為 CMS 昨天在發布 Q&A 方面做得很好,對吧?你可以去讀那份 Q&A,而「36 個月規則」至少已經存在十年,甚至可能二十年了。任何針對居家健康或安寧療護資產的特定收購,你仍然必須遵守 36 個月規則,而這一直都在,沒有新東西。沒有任何會限制我們做一些正常事情的規定,例如搬遷地址或我們平常會做的那些正常作業。
I think in the Q&A, they did a good job of laying that out, and we don't see it having any impact on future M&A in that space as well. Then again, I think they're targeting bad actors, and I think they were thoughtful in this to release the fact that they were not intending to punish good actors and reputable providers like us. Thanks, Ben.
我認為在 Q&A 裡,他們把這些說得很清楚,我們也不認為這會對該領域未來的併購造成任何影響。再說一次,我認為他們是在鎖定不良行為者,而且在這次發布中也很審慎地表明,他們無意懲罰像我們這樣的良好行為者與具公信力的供應商。謝謝你,Ben。
Operator
Operator
Brian Tanquilut, Jefferies.
Brian Tanquilut,Jefferies。
Brian Tanquilut - Equity Analyst
Brian Tanquilut - Equity Analyst
Maybe I'll add to Matt's pot here for a little bit. Jeff, question for you. I appreciate the answer to Ben's question. Just want to clarify, the moratorium is only on the Medicare home nursing side, right? Then I guess the second part of my regulatory question would be, when we think about the core PDN business in the context of all the scrutiny we're seeing in private duty or, personal care services and their Medicaid, just want to make sure that your business is not impacted and you're not seeing anything there.
我可能也來替 Matt 的獎金池加點料。Jeff,想請教你一個問題。我很感謝你對 Ben 的問題所做的回答。只是想確認一下,這個暫停令只針對 Medicare 的居家護理那一側,對吧?那我監管面的第二個問題是,當我們在私人護理(private duty)或個人照護服務(personal care services)以及其 Medicaid 相關的各種審視之下,來看核心 PDN 業務時,只是想確認你們的業務沒有受到影響,而且你們也沒有看到那邊有任何狀況。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
No, great question, Brian, I'll answer it in two parts. One, again, kudos to CMS. I thought they were very thoughtful in how they put the information out there yesterday. They did talk about Medicaid and CHIP programs, right? They certainly are encouraging states to be thoughtful in how states audit the Medicaid and CHIP programs. They also were crystal clear that it did not impact Medicaid and Medicaid reimbursement.
沒有,很好的問題,Brian,我分兩部分回答。第一,再次稱讚 CMS。我覺得他們昨天在資訊發布方式上非常審慎。他們確實提到了 Medicaid 與 CHIP 計畫,對吧?他們也確實在鼓勵各州在審計 Medicaid 與 CHIP 計畫時要審慎。他們同時也非常清楚地表示,這不影響 Medicaid,也不影響 Medicaid 的給付。
The second part is we do operate under a significant number of Medicare provider numbers to get our Medicaid license in certain states. We have many Medicare provider licenses in our PDN business. It's just to have the right to do business to have a Medicaid license. Again, no impact to our Medicaid business, to your point.
第二部分是,我們在若干州取得 Medicaid 執照時,確實是透過相當多的 Medicare 供應商編號(provider numbers)來運作。我們在 PDN 業務中持有許多 Medicare 供應商執照。那只是為了取得經營資格、以便擁有 Medicaid 執照。再次強調,對我們的 Medicaid 業務沒有影響,正如你所說。
Again, I think more thoughtfully as we think of growing our Medicare business, we put the business together through four acquisitions over the last five years. The rest of it's been organic growth the last three years. Nothing that we have reviewed in yesterday's announcements would say that we can't continue an M&A strategy, a thoughtful M&A strategy in our Home Health & Hospice business.
同樣地,更審慎地來看,當我們思考如何成長我們的 Medicare 業務時,我們在過去五年透過四次收購把這個業務整合起來;其餘部分則是在過去三年靠有機成長。就我們對昨天公告內容的檢視,沒有任何地方顯示我們不能在居家健康與安寧療護業務中,持續採取併購策略、審慎的併購策略。
Brian Tanquilut - Equity Analyst
Brian Tanquilut - Equity Analyst
I appreciate that. Matt, this one's for you. When I think of the guidance for the year, just curious if you can call out the cadence that we should be thinking about, especially from Q1 to Q2, given some of the one-timers that were in the quarter. Thanks.
了解,謝謝。Matt,這題給你。當我看今年的指引時,我想請你談談我們應該如何看待節奏,特別是從 Q1 到 Q2,考量到本季有一些一次性項目。謝謝。
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
Yeah, great question there, Brian. I'll first start off by saying how proud we are of all three of our divisions and all three teams. Significant organic growth in all three operating divisions. They really drove great financial performance and the financial results that you're seeing today, but they also drove phenomenal clinical performance in the background as well.
好,Brian,這是個很好的問題。我先說,我們對三個事業部與三個團隊都非常自豪。三個營運事業部都有顯著的有機成長。他們帶動了非常好的財務表現,也帶來你今天看到的財務結果;同時在背後也推動了卓越的臨床表現。
All that being said, we continue to see very, very strong cash collections in Q1 on some previously reserved AR. Really that was to the tune of about $6 million. That impacted both our revenue and our EBITDA in the quarter itself, so a little bit heightened in the quarter. I know we've said this for quite a few quarters now, but we're continuing to win.
在此基礎上,我們在 Q1 仍看到非常、非常強勁的現金回收,來自先前已提列準備的部分應收帳款(AR)。金額大約是 600 萬美元。這在本季同時影響了我們的營收與 EBITDA,因此本季略為偏高。我知道我們已經講了好幾季,但我們仍在持續勝出。
It's really because of the artificial intelligence and the automation that the teams have put in on our RCM department. It's allowed us to really reduce our DSO, improve our cash collections, and shift some of our capacity to go grab some of that aged AR that we thought previously was uncollectible. We're going to continue to push that forward and remain focused on artificial intelligence, especially in our RCM department, because we're seeing such wonderful results from it.
這主要歸功於團隊在我們的 RCM 部門導入的人工智慧與自動化。它讓我們能夠真正降低 DSO、改善現金回收,並把部分產能轉去追回一些帳齡較久、我們先前認為不可收回的應收帳款。我們會持續推進,並持續聚焦人工智慧,特別是在 RCM 部門,因為我們從中看到非常好的成果。
Just one plug I'll put in there as a reminder for more of a Q2 item itself there. In 2025, we did benefit from about $11 million of that timing related business or timing related items. If you exclude those, Brian, for 2025, we still expect to see really solid EBITDA growth in Q2 of 2026. Once again, proud of the teams, what we've been able to accomplish, not only on the cash collection side, clinical side, but most importantly, the operational and the organic growth side too.
我再補充一點,作為提醒,這比較偏向 Q2 的事項。2025 年我們確實受惠於約 1,100 萬美元的時點相關業務或時點相關項目。如果把那些排除,Brian,對於 2025 年而言,我們仍預期在 2026 年 Q2 看到相當扎實的 EBITDA 成長。再次為團隊感到驕傲,我們不僅在現金回收、臨床面有所成果,更重要的是在營運與有機成長面也做到了。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Matt, great answer. I think, as you think of the build this year be a little bit different. Normally, Q1 is one of our lowest EBITDA quarters. I think from what Matt just said, our build will be a little bit different this year where Q1 was, I think as Matt laid out, $5 million to $6 million stronger than we had expected to be both on the revenue and EBITDA side.
Matt,回答得很好。我想,當你思考今年的成長堆疊(build)會有點不同。通常 Q1 是我們 EBITDA 最低的季度之一。我想依 Matt 剛才所說,今年的堆疊會有些不同,因為 Q1 如 Matt 所述,在營收與 EBITDA 兩方面都比我們原先預期強了大約 500 萬到 600 萬美元。
Our build to Q2 will be a little bit less than it normally is. Still, I think as Matt laid out, we expect to have a strong, very strong Q2, if you back out the $11 million in Q2 of 2025, it'll be a nice year-over-year continued growth. As Matt said, not only the AI and the automation, but also our preferred payer relationships just continue to generate great collections and efficient collections, which is a wonderful opportunity for us. Thanks, Brian.
因此我們從 Q1 到 Q2 的增幅會比平常小一些。不過,我認為如 Matt 所說,我們仍預期 Q2 會很強、非常強;如果把 2025 年 Q2 的那 1,100 萬美元扣除,年對年仍會是漂亮的持續成長。正如 Matt 所說,不僅是 AI 與自動化,我們的優先付款方(preferred payer)合作關係也持續帶來很好的回款與高效率的回款,這對我們而言是很棒的機會。謝謝,Brian。
Operator
Operator
Raj Kumar, Stephens Inc.
Raj Kumar,Stephens Inc.。
Raj Kumar - Equity Analyst
Raj Kumar - Equity Analyst
Maybe just kind of, I know you've talked about some of the preferred payer, kind of wins this year on the Private Duty Services side and maybe kind of thinking about, I think you also talked about adding four to five value-based care contracts within this year too. Maybe just any update on the movement on that front.
我想大概是這樣,我知道你們今年在私人護理服務(Private Duty Services)方面談到一些優先付款方(preferred payer)的勝利;另外我想你們也提到今年會新增四到五個價值導向照護(value-based care)合約。想請問在這方面的進展是否有任何更新。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Yeah, Raj, I think let me step back for a second. We've had a nice tailwind for the last three years of government, state, and federal rate wins, mainly Medicaid driven and preferred payer wins. We started messaging mid last year. We thought the government side of that would start to slow down, or we use the word moderate a lot. I think we've seen that in the second half of 2025 and the early parts of 2026.
是的,Raj,我想先退一步說明一下。過去三年我們受惠於政府端(州與聯邦)的費率上調帶來的順風,主要由 Medicaid 驅動,以及偏好付款方(preferred payer)的勝出。我們從去年年中開始對外傳達,我們認為政府端的那一塊會開始放緩,我們也常用「趨於溫和」這個詞。我想我們在 2025 年下半年以及 2026 年初已經看到這個情況。
What we've also seen is the payer relations and preferred payer is picking up for us. As we exited 2025, we had a nice momentum lead in 2026. We see our preferred payer wins both in PDS, Home Health & Hospice. If you heard, we had our first two additional preferred payers in Medical Solutions in Q1. I think what you'll hear from us this year is an uptick of preferred payer wins, more so than the government rate wins that we're receiving. That's kind of what we expected.
我們同時也看到,付款方關係與偏好付款方這一塊正在為我們加速。隨著 2025 年結束,我們在 2026 年帶著不錯的動能起跑。我們在 PDS、居家健康與安寧(Home Health & Hospice)都看到偏好付款方的勝出。如果你有聽到的話,我們在第一季於 Medical Solutions 拿下了前兩個新增的偏好付款方。我想今年你會聽到我們偏好付款方勝出的增加,會多於我們所獲得的政府費率上調。這大致符合我們的預期。
As you asked, following that will be our value-based agreements, both in PDS and in Home Health as well. Strong start to the year. Clearly, we set a goal to sign five additional agreements in Home Health. We signed four in Q1, clearly we will exceed that goal. Eight preferred payers in PDN, and we signed four in Q1. I think we feel confident we'll break that goal. I think big picture, think of 2026 being more of a preferred payer win and a little more moderated government affairs wins.
如你所問,接下來會是我們的價值導向(value-based)協議,包含 PDS 以及居家健康。年初開局強勁。我們很明確地設定目標:在居家健康新增簽下五份協議;我們在第一季就簽了四份,顯然會超過該目標。PDN 方面有八個偏好付款方,我們在第一季簽了四個。我們有信心會突破那個目標。整體來看,請把 2026 年視為偏好付款方勝出較多、政府事務端的勝出則稍微趨於溫和的一年。
Raj Kumar - Equity Analyst
Raj Kumar - Equity Analyst
Got it. Maybe just following up on the kind of the strategic initiatives within Medical Solutions and the preferred payer strategy there. As you kind of think about the opportunity, is there a way of framing the number of unique patients that are kind of under the preferred payer arrangement, relative to just the number of contracts as we kind of think about the opportunity ahead?
了解。也許再追問一下 Medical Solutions 內部的策略性計畫,以及那邊的偏好付款方策略。當你們思考這個機會時,是否能用某種方式來框架:在偏好付款方安排之下的獨特病患數(unique patients)相對於合約數量,讓我們更好理解未來的機會?
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
Yeah, Raj, over time, we'll continue to release this information as we're continuing to roll out. We're really proud of what the teams are doing and rolling out and finishing up these modernization efforts, which we expect them to complete in Q2. Starting with zero preferred payers at the beginning of last year, working it up to 18 to end 2025, adding two in the fourth quarter itself.
是的,Raj,隨著我們持續推進,我們會逐步釋出這些資訊。我們對團隊正在做的事非常自豪:推動並完成這些現代化(modernization)工作,我們預期在第二季完成。從去年年初的零個偏好付款方,提升到 2025 年底的 18 個,且僅第四季就新增了兩個。
We are starting to see that pipeline continue to pull through preferred payers quicker and really put them to the front of the list and valuing those who value our resources and our time, effort, and energy as well. We'll continue to mature this as we sunset or complete our modernization efforts in Medical Solutions. Once we do that, then we'll start releasing additional data on there.
我們開始看到這個管線持續轉化,更快地導入偏好付款方,並且真的把他們放在優先順序最前面,重視那些同樣重視我們資源與我們投入的時間、努力與能量的夥伴。隨著我們在 Medical Solutions 逐步收尾或完成現代化工作,我們會持續讓這套模式更成熟。等完成之後,我們就會開始釋出更多相關數據。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
I think Matt, it's well said. Raj, right now, we would anchor to 4.5% organic year-over-year growth and a 44.7% gross margin.
我想 Matt 說得很好。Raj,就目前而言,我們會以年對年 4.5% 的有機成長,以及 44.7% 的毛利率作為基準。
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
7.4% revenue growth, which has some preferred payer work in there.
7.4% 的營收成長,其中包含一些偏好付款方相關的工作。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
I think, Raj, that shows you we're back to growing this business. It's the first quarter we've hit 93,000 unique patients served in a quarter. To Matt's point, our margin profile is working, our outcomes are successful, our collections are working. That business, to your question, is beginning to act like the other two businesses on our preferred payer. You guys have been under the hood now for almost 18 months working really hard. Shout out to our Med Solutions team. They have really done a lot of work over the last 1.5 year to get this model in place. Thanks, Raj.
我想,Raj,這顯示我們回到這個業務的成長軌道。這是我們首次在單一季度服務到 93,000 名獨特病患。呼應 Matt 的觀點,我們的毛利結構正在發揮作用、臨床結果是成功的、收款(collections)也運作良好。就你問的那點而言,這個業務開始像另外兩個業務一樣,在偏好付款方模式下運作。各位在內部深耕將近 18 個月、非常努力。也要特別感謝我們的 Med Solutions 團隊,他們在過去一年半做了大量工作,才把這個模式建立起來。謝謝你,Raj。
Operator
Operator
Benjamin Rossi, J.P. Morgan.
Benjamin Rossi,J.P. Morgan。
Benjamin Rossi - Analyst
Benjamin Rossi - Analyst
Regarding 1Q margin dynamics, I imagine you got some margin lift quarter-over-quarter with the 53rd week dynamic in 4Q. You mentioned the AI contribution here too in RCM. I guess, as you've been assessing the cost structure in context of your long-term margin profile, can you walk us through how expenses trended during 1Q compared to your expectations and how you're thinking about expense trends within your revised 2026 outlook?
關於第一季毛利率的變動,我想你們在第四季因第 53 週的因素,季度對季度應該有一些毛利率抬升。你也提到 AI 在 RCM 的貢獻。我想問的是:當你們在長期毛利率結構的脈絡下評估成本結構時,能否說明第一季費用相較於你們預期的走勢,以及你們如何看待在修訂後的 2026 年展望中費用趨勢?
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
I would tell you, great question, very thoughtful too, Ben. At the same time, thinking about that 53rd week transitioning over and grabbing a few payroll tax dollars in Q4 2025 opposed to Q1 2026. Really the most impactful one was that $6 million I referenced earlier that hit our EBITDA or that hit our revenue and EBITDA line item. If you still normalize that out, we're in a very great position for Private Duty Services, really sitting around that 28% gross margin, right in line with our expectations of where we should be.
Ben,我會說這是個很好的問題,也非常有深度。同時也要考量第 53 週的轉換,把 2025 年第四季的一些薪資稅(payroll tax)金額帶走,而不是落在 2026 年第一季。真正影響最大的是我先前提到的 600 萬美元,反映在我們的 EBITDA,或是反映在營收與 EBITDA 的科目上。如果把那個因素正常化(normalize)掉,我們的 Private Duty Services 其實處在非常好的位置,毛利率大約在 28% 左右,與我們預期應該達到的水準一致。
On the SG&A side, really impressed with what the teams have been able to accomplish. We're continuing to grow our business organically, continuing to add preferred payer contracts, add additional volumes in all three operating divisions while adding very, very little overhead at the same time.
在 SG&A 方面,我對團隊能做到的成果非常印象深刻。我們持續推動業務有機成長、持續新增偏好付款方合約、在三個營運事業部都增加量能,但同時幾乎沒有增加額外的管理費用(overhead)。
It's really driven by these automation efforts that we've put in place. It's small items at a time. Scheduling, RCM, areas that we think we can get some real good leverage out of. We haven't had to add that incremental overhead as we've continued to grow. I would expect to see what you saw in Q1 pretty consistent with the rest of this year while getting small basis point wins in Q2, Q3, Q4, and continue to ramp that up over time.
這主要是由我們已導入的自動化措施所驅動。一次一點小項目:排班(scheduling)、RCM 等我們認為可以取得很好的槓桿效益的領域。隨著我們持續成長,我們不需要增加那種增量的管理費用。我預期你在第一季看到的情況,會在今年其餘時間相當一致,同時在第二季、第三季、第四季取得一些小幅的基點(basis point)改善,並隨時間持續放大。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
We didn't mention weather, and we have a no excuse policy here at Aveanna, so weather is a fact of life. We did get hit with two major weather events in January. I think to your point, the 53rd week pulled a holiday week into last year, which was nice. That offset probably $1 million worth of payroll taxes and pushed it into last year. We lost about $5.5 million, $6 million of revenue through the two weeks of weather, and that equates to about $1.5 million of margin in EBITDA. We hit these results with playing through that.
我們沒有提到天氣,而 Aveanna 這裡有「不找藉口」的政策,所以天氣是生活的一部分。我們在一月遭遇兩次重大天氣事件。我想如你所說,第 53 週把一個假期週拉到去年,這點不錯;它抵消了大約 100 萬美元的薪資稅,並把它推到去年。我們因那兩週的天氣損失了約 550 萬到 600 萬美元的營收,折算約 150 萬美元的 EBITDA 利潤。我們是在克服這些因素下交出這些結果的。
I think if had you said to us without the weather timing related collections and positive events, we would have ended up in the high 70s, which is probably where we thought this was going to land. Ramping off a high 70s number, I think, to Matt's point, makes the rest of the year make a ton of sense.
我想如果你當時跟我們說:在沒有天氣、時點相關的收款,以及一些正面事件的情況下,我們最後會落在 70 多(high 70s),那大概就是我們原本認為會落點的位置。以 70 多的數字作為起點往後推,我想如 Matt 所說,會讓今年其餘時間的推演非常合理。
Benjamin Rossi - Analyst
Benjamin Rossi - Analyst
Great. Appreciate the added details there. Just a follow-up on the preferred payer contract wins in PDS, and thinking about those preferred payer economics, as penetration of preferred payer mix increases in that segment, do you expect your revenue rate to also re-accelerate, or do you expect growth to continue to be more primarily volume driven with wages absorbing most of this upside on pricing? I guess just curious how you're approaching wage pass-throughs here.
很好,感謝補充這些細節。再追問一下 PDS 的偏好付款方合約勝出,以及偏好付款方的經濟性(economics)。隨著該事業部偏好付款方組合的滲透率提高,你們是否預期營收費率也會重新加速?還是你們預期成長仍主要由量(volume)驅動,而薪資會吸收大部分定價(pricing)的上行?我想了解你們在這裡如何看待薪資轉嫁(wage pass-through)。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
I'd say the latter. I'd say at this point, for the most part, our PDS rate and wage has basically settled in, I think, to the range where we think it will be. It'll move by a percentage point or two, but I don't think it's going to move by $0.50 or $1 per hour. Really proud of how the team started the year. I mean, four wins in Q1. I'm not going to get ahead of myself talking about Q2 yet. Matt will pull me back. Additional wins that we'll be talking about in Q2. The team started this year. We knew we needed more out of preferred payers this year. We knew that was going to have to pick up the slack from more moderated state rate wins.
我會說是後者。我會說就目前而言,大致上我們的 PDS 費率與薪資基本已經穩定在我們認為會落在的區間。它可能會上下變動一到兩個百分點,但我不認為會每小時變動 0.50 或 1 美元。對團隊年初的表現我非常自豪——第一季就拿下四個勝出。我不會搶先談第二季,Matt 會把我拉回來。不過第二季我們還會談到更多新增勝出。團隊今年一開始就知道:今年我們需要偏好付款方提供更多貢獻;我們也知道這必須補上州政府費率上調趨於溫和所留下的缺口。
As I mentioned before, we're seeing that. I think the majority of this will continue to drive volume, and you'll see a pretty consistent spread in that low $12 range moving forward. Again, really, really proud of our preferred payer teams. They are doing an amazing job.
如我先前提到的,我們正在看到這點。我認為其中大多數仍會持續推動量的成長,而你會看到未來維持在 12 美元出頭(low $12 range)的相對穩定差距(spread)。再次強調,我對我們的偏好付款方團隊感到非常、非常自豪,他們做得非常出色。
Operator
Operator
Sean Dodge, BMO Capital Markets.
Sean Dodge,BMO Capital Markets。
Sean Dodge - Analyst
Sean Dodge - Analyst
Maybe just staying on PDS for another moment. You talked about before that segment returning to a 5% to 7% organic growth for this year. Just any updated thoughts on that? If we look at what you all did in Q1 in terms of hours and kind of revenue per hour and just annualize that alone gets me a bit above the high end of that range. I know Thrive contributes some there, but it also is not adjusting for the extra week, Matt, that you mentioned, the weather, or factoring in any additional rate increases or any new preferred payers you're talking about. Just trying to square that and make sure I'm not missing any one-timers or anything else impacting kind of Q1 and how we think about that annualizing over the year.
也許再在 PDS 上多停留一下。你們之前談到該事業部今年會回到 5% 到 7% 的有機成長。對此有沒有更新的看法?如果我們看你們第一季在工時(hours)以及每小時營收(revenue per hour)的表現,單純把它年化就讓我略高於該區間的上緣。我知道 Thrive 會貢獻一些,但這也沒有調整你提到的額外一週(extra week)、天氣影響,或納入任何額外的費率上調或你們提到的新偏好付款方。只是想把這些對起來,確認我沒有漏掉任何一次性因素(one-timers)或其他影響第一季、以及我們如何把它年化到全年思考的因素。
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
No, I don't think you are, Sean. We're continuing to see really impressive growth across our PDS segment and from our PDS teams itself. When you start normalizing out the Thrive acquisition, we still had growth in the high single digits on revenue, which was really, really impressive. We will pass that in Q2 because we closed that acquisition on 6/2/2025, you'll see that start to drop back down.
不,Sean,我不認為是那樣。我們持續看到我們的 PDS 業務板塊以及 PDS 團隊本身都有非常亮眼的成長。當你把 Thrive 併購案的影響正常化之後,我們的營收仍有高個位數的成長,這真的、真的很令人印象深刻。我們會在第二季跨過那個基期,因為我們是在 2025/6/2 完成那筆併購,你會看到那個影響開始回落。
We are seeing moderation starting to occur through there. 60.4%, phenomenal. Close to double digits growth, phenomenal. That will eventually mature over time. We just want to be open and honest with people and understand that, hey, we underpinned this division to a much lower growth rate, though we are accelerating at the time.
我們確實看到那裡開始出現趨緩。60.4%,非常出色。接近兩位數的成長,非常出色。這終究會隨時間成熟。我們只是希望對大家保持開放與誠實,讓大家理解:嘿,我們在規劃這個事業部時,是以更低的成長率作為基礎假設,儘管我們目前正在加速。
Sean Dodge - Analyst
Sean Dodge - Analyst
Okay, great. On the tech or the AI initiatives, Matt, you referenced your work in revenue cycle. You've also talked before about now tackling more front office type functions with that. I was wondering if you just kind of help frame for us, like what proportion of your OpEx, so I guess this would be like the things within the branch and regional admin and your corporate expense line. Like, what percent of those do you think is ultimately like impactable with technology over time? Like what inning do you think we are in when it comes to kind of leveraging tech to drive more efficiency and savings?
好的,很棒。關於科技或 AI 的計畫,Matt,你提到你們在收入循環(revenue cycle)方面的工作。你之前也談過,現在要用它來處理更多前台(front office)類型的職能。我想請你幫我們框架一下:你們的營運費用(OpEx)中,像是分公司與區域行政,以及你們的公司費用那一行,這些項目裡你認為長期來看有多少比例最終是可以透過科技來產生影響的?就利用科技來提升效率與節省成本而言,你覺得我們現在大概在第幾局?
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
Yeah. Sean, top of the first inning, bottom of the first inning. Yeah, but we're still changing sides right here early in the game. We are seeing benefits from it, but we're just being very thoughtful. We're not diving headfirst into the shallow end without wading into it first and making sure to see how deep it actually is. We have seen benefits in that RCM.
是的。Sean,第一局上半、第一局下半。是的,但我們現在還在比賽很早的階段、剛換邊而已。我們確實看到一些效益,但我們非常審慎。我們不會在沒有先試水溫、確認水到底有多深之前,就一頭栽進淺水區。我們在 RCM(收入循環管理)上已經看到效益。
I'm really proud of the teams for leaning in and really being able to drive better results, reduce our DSO, collect cash a lot faster. Also on the operational side of it, between scheduling, between the automation work that a lot of our teams are doing in the Medical Solutions with Tennr, what our accounting teams are doing as well.
我真的為團隊感到很自豪,他們積極投入,確實能推動更好的成果、降低我們的 DSO(應收帳款週轉天數)、更快收回現金。另外在營運面,包含排班、我們許多團隊在 Medical Solutions 與 Tennr 所做的自動化工作,以及我們會計團隊所做的事情。
These are areas that we're just chipping away at it, and we're getting better, and we're getting smarter, and we're getting faster every single day. I would tell you it's still very, very early to crown any champions out here, but we're going to continue to lean in and get the results that we can from it.
這些領域我們就是一點一滴地改善,我們每天都在變得更好、更聰明、更快。我會告訴你,現在要在這裡封誰為冠軍還非常、非常早,但我們會持續加大投入,盡可能從中取得我們能取得的成果。
Operator
Operator
John Ransom, Raymond James.
John Ransom,Raymond James。
John Ransom - Analyst
John Ransom - Analyst
Just to hit on the obvious, you beat by $13 million, you raised by $10 million. Is there anything going on here other than just conservatism?
先談顯而易見的:你們超出預期 1,300 萬美元,你們上調指引 1,000 萬美元。這裡除了保守之外,還有其他因素嗎?
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
No, I think, well, yes. Let's start with the $6 million of timing related, John. Again, I know we sound like a broken record, right? Because it's three out of four quarters in a row we've talked about positive benefits to revenue and earnings. We recognize that at some point [Poster's] going to bake that into our baseline. We think of the quarter in as in the high 70s number, sub 80 number of EBITDA generated out of the quarter based on the results in the quarter. The other $5 million to $6 million being more of lagged AR that was then collected that we were able to take. We think of basing off of the high 70s.
不,我認為——嗯,是的。John,我們先從 600 萬美元的時點因素開始。再次強調,我知道我們聽起來像跳針,對吧?因為連續四個季度裡有三個季度,我們都談到營收與獲利的正向挹注。我們也理解,某個時點起,[Poster's] 會把這些納入我們的基準。我們看這一季,依本季結果,EBITDA 產出大約是 7,000 多萬美元、低於 8,000 萬美元。其餘 500 萬到 600 萬美元,更多是滯後的應收帳款(AR)被收回後,我們得以認列。我們會以 7,000 多萬美元作為基礎。
John Ransom - Analyst
John Ransom - Analyst
Okay.
好的。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Really the normal step up to Q2 would be kind of where we were in Q1, kind of a mid-80s. I think certainly it's still early in the year. We're still seeing things shake out. $10 million for us in EBITDA, John, was aggressive. Thank you. We felt like we were being aggressive, but appreciate the conservatism question.
通常第二季相較第一季的正常上升幅度,會大概落在第一季的水準,也就是 8,000 多萬美元的中段。我想當然現在仍是年初,很多事情還在發展中。對我們而言,John,EBITDA 上調 1,000 萬美元是積極的。謝謝。我們覺得自己已經很積極了,但也感謝你提到保守性的問題。
John Ransom - Analyst
John Ransom - Analyst
Yeah. The other thing, I know you don't guide for Family First, but assuming we put that in our model, how should we think about 3Q, 4Q EBITDA contribution?
是的。另一件事,我知道你們不對 Family First 提供指引,但假設我們把它放進模型裡,對於第三季、第四季的 EBITDA 貢獻,我們應該怎麼看?
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Yes.
是的。
John Ransom - Analyst
John Ransom - Analyst
From that deal?
就那筆交易而言?
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Great question.
好問題。
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
Yeah, John, we're really excited for this Family First acquisition and really the Family First team and bringing them into the Aveanna family. They've got a great focus on clinical outcomes. They have really, really good operational discipline as well, which brings them in culturally and strategically a nice fit for us. That transaction, we talked about valuing it about 7.5x post synergy EBITDA itself, you can back into the math on that one based upon closing date. Then revenue's been sitting around the $120 million mark itself. Depending on closing time of it, we'll come and update our guidance accordingly. Right now, we've just left it out without knowing exactly when that date's going to occur.
是的,John,我們對這次收購 Family First 感到非常興奮,也對 Family First 團隊加入 Aveanna 大家庭感到非常期待。他們非常重視臨床結果,也有非常、非常好的營運紀律,無論在文化上或策略上,對我們而言都是很好的契合。我們談到這筆交易的估值大約是協同效益後 EBITDA 的 7.5 倍,你可以依交割日期把數字倒推回去。營收大約在 1.2 億美元左右。視交割時間而定,我們會再更新指引。目前我們先把它排除在外,因為還不確定確切會在什麼日期發生。
John Ransom - Analyst
John Ransom - Analyst
But I think, I think, Matt --
但我想,我想,Matt——
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
Go ahead.
你先說。
John Ransom - Analyst
John Ransom - Analyst
My point being like, is the post synergy EBITDA, I assume that's not going to be realized right off the bat, just kind of a make our own journey on how long it makes you get to that post synergy EBITDA number.
我的意思是,協同效益後的 EBITDA,我假設不會立刻就實現;只是想了解你們大概需要多久,才能走到那個協同效益後 EBITDA 的水準。
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
Yeah, we're pretty quick on it itself. To get on a full run rate basis.
是的,我們在這方面動作很快。要達到完整的 run-rate(年化運行)基礎。
John Ransom - Analyst
John Ransom - Analyst
Okay.
好的。
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
It takes about six months, John, to get to our kind of hard number itself. We start bringing it in day one. We'll go recognize it, tuck them onto our systems, bring them onto our platforms, put them on our payroll process, put them in our operating model as well. When all that happens, that takes a grand total of six months, and then there's that lag of AR that runs down. That full synergy recognition is in with that 180 day period.
John,大約需要六個月,才能達到我們所說的那個比較「硬」的數字。我們從第一天就開始導入。我們會認列、把他們併入我們的系統、導入我們的平台、納入我們的薪資流程,也納入我們的營運模式。這些全部做完,總共大約六個月,接著還有應收帳款(AR)逐步消化的滯後。完整的協同效益認列會落在那 180 天期間內。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
John, if we use Thrive from last year, we closed Thrive on June 1st, June 2nd. We were effectively done by Thanksgiving.
John,如果我們用去年的 Thrive 當例子,我們在 6 月 1 日、6 月 2 日完成 Thrive 的交割,我們基本上到感恩節就做得差不多了。
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
Yeah.
是的。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
December 1. AR is still running off today. We expect to close this by the end of June, 1st of July. To Matt's point, we would be done by December. By Christmas or holidays, we would be done. Again, AR would run off through the majority of 2027. Low-hanging fruit. This is a great company. Matt's point, great culture, fits right in our wheelhouse. This kind of stuff we should be doing.
12 月 1 日。AR 到今天仍在消化。我們預期這次會在 6 月底、7 月 1 日完成交割。就像 Matt 說的,我們到 12 月就會完成;到聖誕節或假期前就會完成。再次強調,AR 會一路消化到 2027 年的大部分時間。這是低垂的果實。這是一家很棒的公司。正如 Matt 所說,文化很棒,完全符合我們的核心能力。這類事情就是我們應該做的。
John Ransom - Analyst
John Ransom - Analyst
I'm sorry to drag this out, is the first, the rate that you have versus the rates they might have, is that captured immediately, or do you have to go through a contracting cycle?
抱歉我把這個問題拖長了:你們的費率相對於他們可能拿到的費率,這個差異是會立刻反映嗎?還是你們必須走一個重新簽約的週期?
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Here's the beauty, John. We don't know. We stay out of that for the right regulatory review process. We do not operate around rate knowledge.
John,妙就妙在這裡:我們不知道。我們會為了正確的法規審查流程而避開這件事。我們不會在費率資訊的基礎上運作。
John Ransom - Analyst
John Ransom - Analyst
Okay.
好的。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
None of our assumptions are built on any kind of rate arbitrage. We just focus on filling in the geography that we didn't have, that they do, the density that they had in certain Florida markets that we didn't even service. Really filling out needed geography for us in key markets like Florida was the most important reason. We're excited.
我們的任何假設都不是建立在任何形式的費率套利上。我們只專注於補足我們原本沒有、但他們有的地理覆蓋,以及他們在佛羅里達某些市場的密度——那些市場我們甚至沒有提供服務。對我們而言,在佛羅里達等關鍵市場補齊必要的地理覆蓋,是最重要的原因。我們很興奮。
Operator
Operator
Andrew Mok, Barclays.
Andrew Mok,Barclays。
Andrew Mok - Analyst
Andrew Mok - Analyst
Your Home Health episodic mix was north of 80% in the quarter and well above the 75% target. Can you help us understand the trends underneath that? How much of this positive trend is driven by Medicare Advantage versus traditional Medicare? To the extent this is driven by Medicare Advantage, why wouldn't this number sustain at these levels or tick higher as you target more preferred payer agreements? Thanks.
你們本季居家健康(Home Health)的按期(episodic)組合占比超過 80%,明顯高於 75% 的目標。你能幫我們理解背後的趨勢嗎?這個正向趨勢有多少是由 Medicare Advantage 相對於傳統 Medicare 所驅動?如果這主要是由 Medicare Advantage 驅動,那麼當你們鎖定更多優先付款方(preferred payer)協議時,為什麼這個比例不會在這些水準維持,甚至再往上?謝謝。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Hey, Andrew. Good morning. Thanks for noticing that. Again, we've been in the high 70s now for, I'll call it four quarters in a row. We've been flirting with 80% towards the end of last year. We had said that 80 we felt like was kind of the peak. At this point, Andrew, more managed, more Medicare Advantage payers are getting comfortable with the episodic nature. It's some form of Medicare minus 5%, 10%. They're not all set at Medicare episodic rates. As they get more comfortable with this, the growth is just working for us.
嗨,Andrew,早安。謝謝你注意到這點。再次強調,我們現在已經連續四個季度都在 70% 後段。我們在去年底時就一直在逼近 80%。我們曾說過 80% 我們覺得大概是高點。就目前而言,Andrew,更多的管理式、更多的 Medicare Advantage 付款方,正在對按期(episodic)的模式感到更安心。它大概是 Medicare 減 5%、10% 之類的形式;並不是全部都設定在 Medicare 的按期費率。當他們對這種模式越來越熟悉,成長就會對我們有利。
We're able to add -- we mentioned in Q1 we added four new contracts, the majority of those were Medicare Advantage contracts. And they were all episodic, right? At the end of the day, I think we see this number staying in the high seventies. We've not adjusted our target to eighty or above at this point. Don't know that we will, but we've been pretty consistent now for two or three quarters in that high 70s, low 80s. I don't think it's going to change as we continue to sign more Medicare Advantage contracts. They are getting more and more comfortable with this as a form of contracting.
我們也能新增——我們在第一季提到新增了四份新合約,其中大多數是 Medicare Advantage 合約,而且全部都是按期(episodic),對吧?歸根結底,我們認為這個比例會維持在 70% 後段。我們目前還沒有把目標調到 80% 或更高。也不確定會不會調,但我們已經在 70% 後段、80% 初段維持相當一致,大概兩到三個季度了。我不認為在我們持續簽更多 Medicare Advantage 合約的情況下,這會有太大改變。他們對把這作為一種簽約形式,正變得越來越習慣。
Andrew Mok - Analyst
Andrew Mok - Analyst
Great. Maybe just a follow-up. Your capital expenditures increased to $4.5 million in the quarter, which is more than double your typical spend. Can you provide more color on the nature of that and how that's supposed to track for the balance of the year? Thanks.
很好。也許再追問一下。你們本季的資本支出增加到 450 萬美元,這比你們典型的支出高出一倍以上。你能否更詳細說明其性質,以及在今年剩餘期間預計會如何走勢?謝謝。
Deborah Stewart - Senior Vice President, Chief Accounting Officer
Deborah Stewart - Senior Vice President, Chief Accounting Officer
Andrew, it's that Q1 purchase was really related to a laptop refresh that. We had kind of baked in and were expecting. It's not going to continue. That trend won't continue through the rest of the year. It was really a one-time kind of purchase on our laptops.
Andrew,主要是第一季那筆採購其實與筆電汰換更新有關,這原本我們就已經納入規劃並預期會發生。這不會持續下去。這個趨勢不會延續到今年其餘時間。基本上就是一次性的筆電採購。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Great, great. It was our employees' feedback. It was their one of their highest feedback points for us was they wanted new laptops. Good catch, Andrew. Very good catch.
很好、很好。這是我們員工的回饋。對我們而言,他們最高的回饋點之一就是希望換新筆電。Andrew,你抓得很準。非常好的提問。
Operator
Operator
Pito Chickering, Deutsche Bank.
Pito Chickering,德意志銀行。
Pito Chickering - Research Analyst
Pito Chickering - Research Analyst
On PDS, just want to make sure I understand sort of the economics the way you've laid out. You won four preferred contracts in the first quarter, expect to win another four during the year. Yet guiding to, I think, the rate being fairly consistent throughout the year. I mean, wouldn't we see some increase as more preferred come online? Then going back into 2024 on the spread side, it looks like the spread is growing at the same level as the rates. Is that the right way to think about spread going forward, is if rates grow at X%, the spread should grow at the same level?
關於 PDS,我只是想確認我是否正確理解你們所描述的經濟模型。你們在第一季贏得了四個優先合約,並預期今年還會再贏得四個。但你們的指引似乎是,我想,全年費率大致保持一致。我的意思是,隨著更多優先合約上線,我們不應該看到一些提升嗎?另外回到 2024 年的 spread(價差)面向,看起來 spread 的成長幅度與費率的成長幅度相同。這樣理解對嗎?也就是說,若費率成長 X%,那 spread 也應該以相同幅度成長?
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Pito, great question. Thank you. I think, well, one, we're expecting to receive less state government rate wins. The preferred payer contracts we are winning are offsetting some of the more moderated government, state government rate wins that we had received over the last three years, which is why we don't see the rate changing materially. 44%, 43% may go to 44% or 60%, but we don't see it going to 44% or 45% within the course of the year. Yes, I think your thoughts on spread, and Matt would say translate that to gross margin. We think that gross margin will stay in that 28. Could it touch 28.5%? Sure. Could it be 27.6% or 27.7%? Sure.
Pito,問得很好,謝謝。我想,第一,我們預期拿到的州政府費率調升(rate wins)會比較少。我們正在贏得的優先付款方合約,會抵消過去三年我們拿到的、較為溫和的政府(州政府)費率調升,因此我們不認為費率會有實質變動。44%、43% 可能會到 44% 或 60%,但我們不認為在一年之內會到 44% 或 45%。至於你對 spread 的看法,我想 Matt 會把它對應到毛利率。我們認為毛利率會維持在 28% 左右。會不會碰到 28.5%?當然可能。會不會是 27.6% 或 27.7%?也可能。
We think of that being in the 28% range, as well as that spread per hour being somewhere just north of $12. Again, it'll move generally, but yes, we are continuing to pass wage through the four agreements we signed. We have passed wage. We are in the process of passing wage through to those nurses and caregivers as we speak.
我們認為會在 28% 的區間,同時每小時的 spread 大概會在 12 美元以上一點點。同樣地,它會有些波動,但整體而言,是的,我們會持續把薪資透過我們簽署的四份協議傳導出去。我們已經把薪資傳導出去;我們也正在把薪資傳導給那些護理師與照護人員,就在此刻進行中。
Pito Chickering - Research Analyst
Pito Chickering - Research Analyst
Great. With 60% of the PDS revenues coming from preferred, I know you're not giving 2027 guidance at this point, but can you talk about the mechanics of how the annual price increases are set on those preferred contracts as you think about sort of the out years? How much clarity do you have on what this price increases should be by nature of those preferred contracts, because they've already written?
很好。由於 PDS 營收有 60% 來自優先合約,我知道你們目前不提供 2027 年指引,但你能談談在這些優先合約中,年度價格調升是如何設定的機制嗎?就你們對未來幾年的思考而言,對於這些價格調升你們有多大的能見度?因為這些優先合約已經寫進合約了。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
I'd like the re-record reflect that at 10:53 AM on May 14th, you asked for 2027 guidance. That's impressive. Pito, I think as we laid out earlier this year, we thought 57% of the MCO volumes would go to low to mid 60 percentage points. I think based on what we see today, we would say that that's accurate this year. It'd be right in the mid-60s. We've said before publicly, we thought this could get to the low to mid 80% at some point in the future. People have asked us, What inning are you in? It's not the first inning, but it's probably the fifth or sixth inning. We're probably about halfway through this process.
我想請紀錄更正:在 5 月 14 日上午 10:53,你就問了 2027 年的指引。這很厲害。Pito,我想如同我們今年稍早所說,我們原本認為 57% 的 MCO 量會提升到 60% 出頭到 60% 中段。我想以我們今天看到的情況來看,我們會說今年這個判斷是正確的,會落在 60% 中段。我們之前也公開說過,我們認為未來某個時間點可能會到 80% 初段到 80% 中段。大家問我們:你現在打到第幾局?不是第一局,但大概是第五或第六局。我們大概走到這個流程的一半左右。
As it relates to PDS specifically, I'd say in Home Health, we're still in the early stages of this story, and certainly Med Solutions, we're in the very early stages. I think you'll see that somewhere between 3% to 5% volume shift per year, continuing over the next three to five years. There's not a lot of large volume payers for us to sign in our current market. We're down to the very fine minute payers. It's also why when we talk, and Kristy is sitting, our Chief Operating Officer sitting right next to me, we've talked about filling in Ohio and Michigan and West Virginia and Tennessee and Kentucky, filling in some of those additional markets where we have no Medicaid revenue today, no preferred payers.
就 PDS 本身而言,我會說在居家健康(Home Health)方面,我們仍處於這個故事的早期階段;而 Med Solutions 我們更是在非常早期的階段。我想你會看到每年大約 3% 到 5% 的量轉移,並在未來三到五年持續。我們在現有市場中,能簽下的大型量體付款方已經不多了;我們已經剩下非常零碎、很小的付款方。這也是為什麼當我們談到(Kristy 就坐在我旁邊,我們的營運長),我們談到要補齊俄亥俄、密西根、西維吉尼亞、田納西與肯塔基等地,補上那些我們今天沒有 Medicaid 營收、也沒有優先付款方的額外市場。
All of that's new greenfield to us. As we do think about the next three to five years, we want to fill in those geographies, which would create new opportunity for us to add brand new preferred payer, and really just new greenfield for us in the Medicaid space. We said before, our payers, our national MCO payers have asked us and are asking us to move into these markets for them. Thanks, Pito.
對我們而言,那些都是全新的綠地市場。當我們思考未來三到五年時,我們希望把這些地理區域補齊,這將為我們創造新的機會去新增全新的優先付款方,並且在 Medicaid 領域對我們而言真的是新的綠地。我們之前也說過,我們的付款方、我們的全國性 MCO 付款方已經要求我們、也正在要求我們為他們進入這些市場。謝謝你,Pito。
Pito Chickering - Research Analyst
Pito Chickering - Research Analyst
Yeah. When, I guess the follow up there is just, what price increases sort of are baked into these preferred contracts? One of the questions that I keep getting is each quarter, you guys are beating by huge amounts and guidance isn't changing. The buy side tries to figure out what's sort of the true out year numbers. I guess, what percent of your contracts have inflation already built in and kind of any color on sort of what inflation is built into those contracts? Thank you.
是的。我想那個追問就是,這些優先合約裡面大概已經內含了哪些價格調升?我一直被問到的一個問題是:每一季你們都大幅超預期,但指引卻沒有改變。買方會試著推算未來幾年的真正數字。我想問的是,你們有多少比例的合約已經把通膨因素寫進去?以及能否提供一些顏色,說明這些合約中內含的通膨大概是多少?謝謝。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
I don't have the perfect answer the way you asked it other than thank you. Thank you for that comment or the compliment. I think there was a compliment in there. Other than, Pito, all of our contracts are annual and evergreen. We've not, as we've said before, our first preferred payer is still part of the 34 preferred payers today. We've not lost a preferred payer to date. That may change in the future, but not to date.
我沒有辦法用你提問的方式給出完美答案,但還是謝謝。謝謝你的評論或稱讚。我想裡面有一句稱讚。除此之外,Pito,我們所有合約都是年度合約且為 evergreen(自動續約/長期有效)。如同我們之前說過的,我們第一個優先付款方至今仍是今天 34 個優先付款方之一。我們至今沒有失去任何一個優先付款方。未來可能會改變,但截至目前沒有。
Every contract we have is reviewed every year. Matt would even say every quarter, even though they're not quarterly contracts, but our teams are meeting with the payers quarterly. The opportunity for rate enhancement and for additional value-based agreements are there in every one of the contracts every year.
我們的每一份合約每年都會檢視。Matt 甚至會說每一季都在檢視,雖然它們不是季度合約,但我們的團隊每季都會與付款方會面。每一年、每一份合約都存在費率提升以及新增價值型(value-based)協議的機會。
We've also said before that the value-based agreements take normally between nine and about 18 months post the point at which we sign the preferred payer agreement, not because we're not ready, but it just takes the payer time to get comfortable with the fact that they would add on an additional upside bonus to us. Again, the tail on this plays out years in front of us on the value-based side.
我們也曾說過,價值型協議通常需要在我們簽下優先付款方協議之後約 9 到 18 個月才會落地,不是因為我們沒準備好,而是付款方需要時間去建立信心,確認他們願意再加上一個額外的上行獎金給我們。再說一次,價值型這一端的長尾效應會在未來多年逐步展開。
Very few of our agreements have COLA or cost of living type rate increases built into them. Those are annual conversations that we're and by the way, we're not having those every year with them. We're having every other year, every third year, because the upfront rate they're paying us is pretty material compared to the Medicaid fee-for-service schedule. That's probably the best way I can answer the question.
我們的協議中,只有極少數內含 COLA 或生活成本類型的費率調升。這些都是年度對話;而且順帶一提,我們也不是每年都跟他們談,我們可能每兩年、每三年談一次,因為他們一開始付給我們的費率,相較於 Medicaid 按次服務(fee-for-service)的給付表,本來就高出不少。這大概是我能回答這個問題的最佳方式。
Operator
Operator
AJ Rice, UBS.
AJ Rice,瑞銀。
AJ Rice - Analyst
AJ Rice - Analyst
First, just maybe on your comment in the prepared remarks, I think you said that caregiver hiring and retention is strong or is solid. Is that, would you say that's pretty much a function of the rate of environment that you're seeing? Or is there any underlying trend with potential caregiver candidates that suggest things are stabilizing or even improving somewhat?
首先,可能針對你在事先準備的講稿中的評論,我想你說照護人員的招募與留任很強或很穩健。你會說這主要是你們所看到的費率環境所致嗎?還是說,在潛在照護人員候選者方面,有任何底層趨勢顯示情況正在趨於穩定,甚至有些改善?
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
I think you hit it right, AJ. It's being driven by rate and wage, right? The two are moving in unison. kind of to Pito's point, the 12 hours, how that's moving in unison. As our rate goes up, consistently our wage is going up. It's really a function of continuing to get rate wins, turning that into wage improvements and ultimately hiring and employing more caregivers. I wouldn't say it's getting easier. I'd also say it's not getting harder.
我想你說得很到位,AJ。這是由費率與薪資所驅動,對吧?兩者是同步變動的。有點呼應 Pito 的觀點,那個每小時 12 美元(的 spread)是如何同步變動的。隨著我們的費率上升,我們的薪資也會持續上升。這其實就是持續拿到費率調升,將其轉化為薪資改善,最終招募並雇用更多照護人員的結果。我不會說變得更容易;我也會說並沒有變得更難。
Over the last six months, we haven't had, other than the weather type stuff, we've not had a position where we felt like nurse hiring or family caregiver hiring has gotten harder. It's been pretty consistent. The wins, the growth, Matt talked about high single digit PDS growth, organic growth, that's tied to the rate and wage pass-through. Think about accelerated wages tied to accelerated rate.
在過去六個月裡,除了天氣之類的因素之外,我們沒有遇到任何情況讓我們覺得護理師招募或家庭照護人員招募變得更困難。整體相當一致。這些勝利、這些成長——Matt 談到 PDS 的高個位數成長、內生成長——都與費率與薪資的傳導有關。可以把它想成:加速的薪資與加速的費率相互連動。
AJ Rice - Analyst
AJ Rice - Analyst
Okay. I wanted to just ask you a minute about Medical Solutions. You're saying, I think, guiding to mid-single-digit growth near term, but double-digit by year-end. What specifically is going to drive that acceleration? Is that, are you able to cross-sell on these new two acquisitions? Is that part of the dynamic that'll drive more volume into Med Solutions? I think you said also gross margins have stabilized there. Is that stable and that's sort of where we're going to be for a while, or is there improvement potential in Med Solutions as well?
好的。我想花一點時間問一下你們的醫療解決方案(Medical Solutions)。我理解你們的指引是:短期接近中個位數成長,但到年底會到雙位數。具體是什麼會驅動這個加速?是說你們能在這兩項新的收購上做交叉銷售嗎?這是否是推動更多量進入醫療解決方案的動能之一?我記得你們也提到那邊的毛利率已經穩定下來。這個穩定是指會在一段時間內維持在這個水準,還是醫療解決方案也有改善空間?
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
Yeah, AJ, on the gross margin side of this, I would tell you that the 44% range is kind of right down the middle where we expect it to be. Really what you're already seeing in a Medical Solutions division in Q4 and Q1 of this year is the benefits from the modernization efforts already taking hold. As we move through 2026, you've seen us jump up from mid-single digits to the higher end of that at 7.4%. You'll see that continuing to grow to that high single digits, low double digits in the back half of this year. It's really just the completion of our modernization efforts.
是的,AJ,就毛利率這一塊,我會告訴你,約 44% 的區間大概正好落在我們預期的中間值。其實你在醫療解決方案事業部今年的 Q4 和 Q1 已經看到現代化(modernization)努力開始發揮效益。隨著我們進入 2026 年,你也看到我們從中個位數跳升到較高端的 7.4%。你會看到這個趨勢在今年下半年持續成長到高個位數、低雙位數。這主要就是我們現代化工作的完成。
To your point, there's a great cross-sell opportunity in between, our businesses themselves and bringing in the Family First acquisition gives another cross-sell opportunity for that division at the same time. Organic growth is something that this team is ready to start driving. I would tell you, they've been felt left out the past couple of quarters, and they've proved it in Q4 and Q1 so far.
如你所說,我們各個業務之間有很好的交叉銷售機會,而引進 Family First 這項收購,也同時為該事業部帶來另一個交叉銷售機會。有機成長是這個團隊已準備開始推動的事情。我會說,他們在過去幾個季度有點像被忽略了,但他們已在 Q4 和目前為止的 Q1 證明了自己。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
AJ, Matt said, well, automation, AI is a big part of this. We get 5,000 or 6,000 e-faxes a week for this business. The more we can use automation and AI to pull through the referral process and the follow-up physician orders and things that come with it, the more we can pull through growth. We are very pleased with 4.5%. This is all organic, right? This is truly organic. I think we'll see that continue to tick up. Is 10% a little bit aggressive by Q4? Probably. We think high single digits by Q4 and probably low double digits by the time we get into first half of next year.
AJ,Matt 提到,自動化、AI 是其中很大的一部分。這個業務每週會收到 5,000 到 6,000 份電子傳真(e-fax)。我們越能運用自動化和 AI 來推進轉介流程、後續的醫師開立醫囑以及相關事項,我們就越能帶動成長。我們對 4.5% 非常滿意。這全部都是有機的,對吧?這確實是有機成長。我想我們會看到它持續往上走。到 Q4 達到 10% 會不會有點激進?可能是。我們認為到 Q4 會是高個位數,而到明年上半年時可能會到低雙位數。
Operator
Operator
Jared Haase, William Blair.
Jared Haase,William Blair。
Jared Haase - Equity Analyst
Jared Haase - Equity Analyst
I'll just stick to one here as I realize we're getting to the end of the call, but I just wanted to double-click on the Home Health side. Again, nice to see the growth there. You pointed to clinical offerings and success on that front, I think that's been kind of consistent with your commentary the last few quarters. I was just wondering if there's any more, I guess, color or data points you could share to sort of illustrate what you mean by the investment that you've made in terms of clinical outcomes, since that really seems to be underpinning the operational performance here. I guess to be clear, when you talk about clinical investment, is that more kind of in areas around star ratings performance, or is that maybe developing, I guess, specific programs based on the needs of patients and referral partners? Thanks.
我就問一個,因為我知道我們快到電話會議尾聲了,但我想再深入確認一下居家健康(Home Health)這一塊。同樣地,很高興看到那邊的成長。你們提到臨床服務內容(clinical offerings)以及在這方面的成功,我想這跟你們過去幾個季度的評論一致。我想問的是,你們是否能再提供更多細節或數據點,來說明你們所說在臨床結果方面的投資,因為這似乎正是支撐目前營運表現的關鍵。更具體地說,當你們談到臨床投資時,是比較偏向提升星級評等(star ratings)的表現,還是可能在依據病患與轉介合作夥伴需求來開發特定方案?謝謝。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
By the way, great question, Jared. Thank you. Yes, I'll start with TPS scores, right? We're now into the second full year of scoring on TPS scores. I think we mentioned last year we were a net winner, net benefit, so we received value-based payments from Medicare because of our five-star rankings. We are also on pace to be a net winner this year in TPS ranking. Your five-star scoring tells you based on your value-based payments whether you're net winner or net loser. Effectively, we have mitigated some of the rate decrease in the last 18 months in Home Health through our TPS scores. We also have no three-star agencies, both in Home Health or Hospice. We, I think on average, we're 4.5 stars on Home Health --
順帶一提,Jared,問得很好,謝謝你。是的,我先從 TPS 分數開始,好嗎?我們現在已進入 TPS 分數評分的第二個完整年度。我想我們去年提到過,我們是淨受益者、淨贏家,因此因為我們的五星評等而從 Medicare 收到價值導向(value-based)的給付。我們今年在 TPS 排名上也有望成為淨贏家。你的五星評分會根據你的價值導向給付告訴你是淨贏家還是淨輸家。實際上,透過我們的 TPS 分數,我們在過去 18 個月居家健康的費率下調中,已經緩解了一部分影響。我們在居家健康或安寧照護(Hospice)都沒有任何三星機構。我想我們居家健康平均大約是 4.5 星——
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
21 out of 22.
22 個裡面有 21 個。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
21 out of 22 Hospice locations are five-star branches. We have phenomenal performance. The team has rolled out a cardio program that was CHAP approved, they've invested in and actually clinical programs and protocols that we're outselling and outsourcing. I think net takeaway is the team has done a really good job of providing great outcomes, great patient satisfaction in both businesses. We've learned over time, you can't have a great financial outcome without a great clinical outcome. You also shouldn't have a great clinical outcome without a good financial outcome. I think the yin and yang in our HHH business are working right now, great growth and great clinical outcomes.
22 個安寧照護據點中有 21 個是五星分支。我們的表現非常出色。團隊推出了一個獲 CHAP 核准的心臟照護(cardio)方案,他們也投資並實際建立了臨床方案與流程,我們正在把這些拿去對外銷售並外包。我想整體重點是:團隊在兩個業務上都做得很好,提供了很好的結果與很高的病患滿意度。我們一路走來學到的是:沒有很好的臨床結果,就不可能有很好的財務結果;同樣地,有很好的臨床結果,也不應該沒有好的財務結果。我認為我們 HHH 業務的陰與陽目前運作得很好:成長很強、臨床結果也很強。
Operator
Operator
Grayson McAlister, Truist Securities.
Grayson McAlister,Truist Securities。
Grayson McAlister - Analyst
Grayson McAlister - Analyst
This is Grayson on for Dave. Just one for me as well. Wanted to follow up on capital allocation. Obviously, some work left around Family First. Past that, how are you thinking about the potential for tuck-ins in Home Health, just given the regulatory backdrop versus something like adding density in one of those PDS states that you've called out, like in Ohio or Tennessee? Just following on, still right to think about leverage somewhere in that 4x level ending the year. That'll be it for me.
我是代 Dave 發問的 Grayson。我也只有一題。想追問一下資本配置。顯然在 Family First 上還有一些工作要完成。除此之外,在目前的監管背景下,你們如何看待在居家健康領域做補強式收購(tuck-ins)的可能性,相較於例如在你們點名的某些 PDS 州(例如俄亥俄或田納西)增加密度?另外延伸問一下:今年年底槓桿率大約落在 4 倍左右的看法仍然正確嗎?我就這些。
Matthew Buckhalter - Chief Financial Officer
Matthew Buckhalter - Chief Financial Officer
Perfect, Grayson. I think I'll start off on cash flow and end this on leverage here for you. Really, really pleased for the team start to 2026. Our team continues to position Aveanna as a strong free cash flow generator. 2025, obviously monumental year for us. We had about $130 million to $131 million of free cash flow, reflecting not only a commitment to clinical quality, but also cash collections in there as well. We expect this positive momentum to continue into Q1 and the rest of 2026, and the cash flow generation to be pretty consistent with what you saw in 2025. On the leverage side of it, couldn't be more proud of what we've been able to accomplish the last few years on our leverage. We've done a lot.
很好,Grayson。我先從現金流談起,最後再回答你關於槓桿的問題。我們對 2026 年團隊的開局非常、非常滿意。我們的團隊持續把 Aveanna 定位為強勁的自由現金流產生者。2025 年對我們而言顯然是里程碑式的一年。我們大約產生了 1.30 億到 1.31 億美元的自由現金流,這不僅反映我們對臨床品質的承諾,也包含了現金回收(cash collections)的成果。我們預期這股正向動能會延續到 Q1 以及 2026 年其餘時間,而現金流的產生將與你在 2025 年看到的水準相當一致。至於槓桿方面,我對過去幾年我們在槓桿上所達成的成果感到非常自豪。我們做了很多。
We've taken this down from double digits down to 3.8x net leverage here on an LTM basis in Q1. Certainly not done either. Still some more work to do. We'll continue to grow this company, not only organically, but also inorganically, while continuing to keep leverage at top of mind. We want to be highly sensitive to that and highly aware of it. There's still some free cash flow that we could do for small tuck-in acquisitions, but beyond Family First this year, probably nothing monumental.
我們已把槓桿從雙位數降到 Q1 以 LTM(過去十二個月)基礎計算的 3.8 倍淨槓桿。當然我們也還沒做完,還有一些工作要做。我們會在持續把槓桿放在首要考量的同時,繼續推動公司成長,不僅是有機成長,也包括非有機成長。我們希望對此高度敏感、也高度關注。我們仍有一些自由現金流可以用於小型補強式收購,但今年除了 Family First 之外,可能不會有什麼重大的交易。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
I mean, I think that's well said. Part of the goal, Grayson, is to do both, is to grow the company through tuck-ins, but also to continue to delever. I know Matt and the team are very proud. Matt and Debbie lowering leverage, almost a quarter point in the quarter, close to 3.8x, was a continued great movement. We're not done in that avenue. As Matt said, our goal is to get down to at or below 3x leverage and to continue to grow the company. We think we can do both.
我的意思是,我覺得這說得很好。Grayson,我們目標的一部分就是兩者都要做到:透過補強式收購來成長公司,同時也持續去槓桿。我知道 Matt 和團隊都非常自豪。Matt 和 Debbie 在本季把槓桿降低了將近 0.25 倍、降到接近 3.8 倍,這是持續的良好進展。我們在這條路上還沒結束。正如 Matt 所說,我們的目標是把槓桿降到 3 倍或以下,同時持續成長公司。我們認為兩者可以兼得。
Operator
Operator
Thank you. We have reached the end of the question and answer session. I would like to turn the floor back to Jeff Shaner for closing remarks.
謝謝。問答環節到此結束。我想把時間交回給 Jeff Shaner 做結語。
Jeffrey Shaner - President, Chief Executive Officer, Director
Jeffrey Shaner - President, Chief Executive Officer, Director
Awesome. Thank you, operator. Thank you so much for your interest in our company and our Aveanna story, we look forward to catching up with you after the end of Q2 in August. Thank you. Have a great day.
太好了。謝謝你,接線員。非常感謝各位對我們公司以及 Aveanna 故事的關注,我們期待在 8 月 Q2 結束後再與各位交流。謝謝。祝各位有美好的一天。
Operator
Operator
Thank you. This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.
謝謝。今天的電話會議到此結束。您現在可以掛斷電話線。感謝您的參與。